Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide.
Vaccination with a peptide representing a CTL epitope from the human papillomavirus (HPV)16 E7 protein induces a specific CTL response that prevents the outgrowth of HPV16 E7-expressing tumors. In contrast, vaccination with a peptide encoding an adenovirus type 5 (Ad5) E1A CTL epitope results in CTL tolerance and enhanced growth of an Ad5 E1A-expressing tumor. It is unclear why these peptides induce such opposite effects. To determine whether a difference in pharmacokinetics can explain the functional contrasts, tritiated Ad5 E1A and HPV16 E7 peptides were injected into mice. Results show that the tolerizing peptide spread through the body 16 times faster than the activating peptide and was cleared at least 2 times faster. The HPV16 E7 peptide kinetics correlated with the kinetics of HPV16 E7-specific CTL induction. In contrast, Ad5 E1A peptide injection resulted in physical deletion of preexisting Ad5 E1A-specific CTLs within 24 h after injection. This tolerization occurred at the time when the peptide reached its maximum peptide concentration in the organs. These data suggest that ubiquitous expression of the tolerizing Ad5 E1A peptide within a short period of time causes activation-induced cell death of Ad5 E1A-specific CTLs. Therefore, information on the pharmacokinetics of peptides is vital for the safety and efficacy of peptide-based vaccines.
Weijzen
S
S
Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA.
Meredith
S C
SC
Velders
M P
MP
Elmishad
A G
AG
Schreiber
H
H
Kast
W M
WM
D017500:Adenovirus E1A Proteins / Q000008:administration & dosage / Q000276:immunology* / Q000493:pharmacokinetics*; D000818:Animals; D017637:Clonal Deletion; D004058:Diffusion; D018984:Epitopes, T-Lymphocyte / Q000276:immunology / Q000378:metabolism; D005260:Female; D007108:Immune Tolerance / Q000276:immunology*; D007279:Injections, Subcutaneous; D007700:Kinetics; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009856:Oncogene Proteins, Viral / Q000008:administration & dosage / Q000276:immunology* / Q000493:pharmacokinetics*; D009928:Organ Specificity / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology / Q000493:pharmacokinetics; D011485:Protein Binding / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D013997:Time Factors; D014316:Tritium / Q000378:metabolism; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000493:pharmacokinetics
D017500:Adenovirus E1A Proteins; D018984:Epitopes, T-Lymphocyte; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D010446:Peptide Fragments; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16; D014316:Tritium